Status:
COMPLETED
Paricalcitol Injection Phase II Trial
Lead Sponsor:
Abbott
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
20-74 years
Phase:
PHASE2
Brief Summary
The PK and tolerability of paricalcitol after repeated intravenous administration for 2 weeks (total 6 doses at every HD session) are studied in subjects with 2°HPT who are receiving HD 3 times a week...
Detailed Description
The purpose of this study is pharmacokinetic \& tolerability.
Eligibility Criteria
Inclusion
- Subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal failure
Exclusion
- Subject is considered by investigator, for any reason, to be an unsuitable candidate for the study
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00646932
Start Date
November 1 2005
Last Update
March 31 2008
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Gunma, Japan
2
Hokkaido, Japan
3
Ibaraki, Japan
4
Kagoshima, Japan